Societe Generale restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Thursday morning.
A number of other research firms have also recently issued reports on AZN. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($75.50) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($69.44) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Kepler Capital Markets restated a buy rating and set a GBX 5,500 ($74.15) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Liberum Capital restated a buy rating and set a GBX 5,500 ($74.15) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company. AstraZeneca plc currently has a consensus rating of Hold and an average price target of GBX 5,041.09 ($67.97).
AstraZeneca plc (LON:AZN) traded up 3.01% on Thursday, reaching GBX 4912.00. 3,343,608 shares of the company traded hands. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The firm’s market cap is GBX 62.19 billion. The stock has a 50-day moving average price of GBX 4,574.46 and a 200-day moving average price of GBX 4,884.61.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/09/22/astrazeneca-plc-azn-given-buy-rating-at-societe-generale.html.
The firm also recently disclosed a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were issued a GBX 68.90 ($0.93) dividend. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($58.92) per share, with a total value of £1,704.30 ($2,297.83).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.